Insider Selling: SiBone (NASDAQ:SIBN) Director Sells 12,132 Shares of Stock

Key Points

• SiBone Director John Gordon Freund sold 12,132 shares of the company's stock at an average price of $15.99, resulting in a total transaction value of approximately $193,990.68.
• After the sale, Freund's ownership in SiBone decreased by 11.68%, leaving him with 91,767 shares valued at around $1,467,354.33.
• SiBone's stock price recently fell to $15.40, and the company reported a negative earnings per share (EPS) of ($0.14), beating estimates slightly.

SiBone (NASDAQ:SIBN - Get Free Report) Director John Gordon Freund sold 12,132 shares of the company's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $15.99, for a total transaction of $193,990.68. Following the sale, the director owned 91,767 shares of the company's stock, valued at $1,467,354.33. This trade represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

SiBone Price Performance

SiBone stock traded up $0.05 during trading hours on Friday, hitting $15.35. 52,718 shares of the stock were exchanged, compared to its average volume of 430,983. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.00 and a current ratio of 8.38. The stock has a market capitalization of $661.98 million, a P/E ratio of -27.55 and a beta of 0.91. SiBone has a 12 month low of $11.70 and a 12 month high of $20.05. The business's 50-day moving average is $17.41 and its two-hundred day moving average is $16.59.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05. The firm had revenue of $48.63 million for the quarter, compared to analysts' expectations of $48.12 million. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. Equities research analysts expect that SiBone will post -0.78 EPS for the current fiscal year.

Institutional Trading of SiBone

Several large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in SiBone by 4.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company's stock worth $328,000 after buying an additional 988 shares during the last quarter. Invesco Ltd. grew its stake in shares of SiBone by 8.9% during the fourth quarter. Invesco Ltd. now owns 17,203 shares of the company's stock valued at $241,000 after purchasing an additional 1,413 shares during the last quarter. Rhumbline Advisers grew its stake in shares of SiBone by 3.6% during the first quarter. Rhumbline Advisers now owns 59,721 shares of the company's stock valued at $838,000 after purchasing an additional 2,100 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new stake in shares of SiBone during the first quarter valued at approximately $34,000. Finally, Barclays PLC grew its stake in shares of SiBone by 2.7% during the fourth quarter. Barclays PLC now owns 99,212 shares of the company's stock valued at $1,391,000 after purchasing an additional 2,589 shares during the last quarter. 98.11% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Wall Street Zen lowered shares of SiBone from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Truist Financial increased their price target on shares of SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Cantor Fitzgerald set a $25.00 price target on shares of SiBone and gave the stock an "overweight" rating in a research report on Monday. Finally, Needham & Company LLC reissued a "buy" rating and issued a $24.00 price target on shares of SiBone in a research report on Tuesday, May 6th.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.